A humanized anti-M2 scFv shows protective in vitro activity against influenza.

M2 is one of the most conserved influenza proteins, and has been widely prospected as a potential universal vaccine target, with protection predominantly mediated by antibodies. In this paper we describe the creation of a humanized single chain Fv from 14C2, a potent monoclonal antibody against M2. We show that the humanized scFv demonstrates similar activity to the parental mAb: it is able to recognize M2 in its native context on cell surfaces and is able to show protective in vitro activity against influenza, and so represents a potential lead antibody candidate for universal prophylactic or therapeutic intervention in influenza.

[1]  A. Jegerlehner,et al.  Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity , 2004, The Journal of Immunology.

[2]  K. Okuda,et al.  Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. , 2001, Vaccine.

[3]  W. P. Glezen,et al.  Control of influenza. , 2004, Texas Heart Institute journal.

[4]  A R Rees,et al.  Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies. , 1994, Journal of molecular biology.

[5]  C. Chothia,et al.  Domain association in immunoglobulin molecules. The packing of variable domains. , 1985, Journal of molecular biology.

[6]  R. Poljak,et al.  Preliminary crystallographic study of the complex between the Fab fragment of a monoclonal anti-lysozyme antibody and its antigen. , 1983, Journal of molecular biology.

[7]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[8]  M. Bray,et al.  Current and future antiviral therapy of severe seasonal and avian influenza , 2008, Antiviral Research.

[9]  R. Couch,et al.  Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2 , 2006, Virology Journal.

[10]  G. Winter,et al.  Making antibodies by phage display technology. , 1994, Annual review of immunology.

[11]  L. Otvos,et al.  Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus. , 2006, Molecular immunology.

[12]  J. Farrar,et al.  Prophylactic and Therapeutic Efficacy of Human Monoclonal Antibodies against H5N1 Influenza , 2007, PLoS medicine.

[13]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[14]  K. Whaley,et al.  Preventing infectious disease with passive immunization. , 2000, Microbes and infection.

[15]  H. Yoshida,et al.  Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. , 2008, Antiviral research.

[16]  F. Hayden,et al.  Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. , 1992, Current topics in microbiology and immunology.

[17]  Daniele Sblattero,et al.  Exploiting recombination in single bacteria to make large phage antibody libraries , 2000, Nature Biotechnology.

[18]  T. Tumpey,et al.  Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1 , 2007, Emerging infectious diseases.

[19]  Larisa V. Gubareva,et al.  Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants , 2001, Antimicrobial Agents and Chemotherapy.

[20]  G. Studnicka,et al.  Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. , 1994, Protein engineering.

[21]  K. Mozdzanowska,et al.  Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. , 1999, Virology.

[22]  I. Barr,et al.  The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. , 2007, Antiviral research.

[23]  Janice M Reichert,et al.  Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.

[24]  S. Reis,et al.  Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity. , 2000, Circulation.

[25]  N. Lonberg.  Human antibodies from transgenic animals , 2005, Nature Biotechnology.

[26]  R. Tripp,et al.  Recombinant vaccines for influenza virus. , 2008, Current opinion in investigational drugs.

[27]  S. D. Gorman,et al.  A humanized monovalent CD3 antibody which can activate homologous complement , 1991, European journal of immunology.

[28]  J Saldanha,et al.  Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. , 1991, Protein engineering.

[29]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[30]  L. Zentilin,et al.  Anti-idiotypic response in mice expressing human autoantibodies. , 2008, Molecular immunology.

[31]  R. Lamb,et al.  Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly. , 1995, Virology.

[32]  Cinque S. Soto,et al.  Structural basis for the function and inhibition of an influenza virus proton channel , 2008, Nature.

[33]  A. Moscona.  Neuraminidase inhibitors for influenza. , 2005, The New England journal of medicine.

[34]  T. Tumpey,et al.  Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. , 2006, Vaccine.

[35]  J. Shiver,et al.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. , 2004, Vaccine.

[36]  R. Siegel,et al.  Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. , 2005, Journal of molecular biology.

[37]  N. Cox,et al.  Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. , 2006, JAMA.

[38]  J. C. Almagro,et al.  Use of human germline genes in a CDR homology-based approach to antibody humanization. , 2005, Methods.

[39]  K. Subbarao,et al.  Can Immunity Induced by the Human Influenza Virus N1 Neuraminidase Provide Some Protection from Avian Influenza H5N1 Viruses? , 2007, PLoS Medicine.

[40]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[41]  J. Chou,et al.  Structure and mechanism of the M2 proton channel of influenza A virus , 2008, Nature.

[42]  R. Webster,et al.  Comparison of Efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and Other Avian Influenza Viruses , 2001, Antimicrobial Agents and Chemotherapy.

[43]  Xiyan Xu,et al.  Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern , 2005, The Lancet.

[44]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[45]  John Bartlett,et al.  Planning for Avian Influenza , 2006, Annals of Internal Medicine.

[46]  K. Mozdzanowska,et al.  Influenza Type A Virus Escape Mutants Emerge In Vivo in the Presence of Antibodies to the Ectodomain of Matrix Protein 2 , 2005, Journal of Virology.

[47]  J. Reichert,et al.  Anti-infective monoclonal antibodies: perils and promise of development , 2006, Nature Reviews Drug Discovery.

[48]  R. Lamb,et al.  Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions , 1988, Journal of virology.

[49]  B. Wahrén,et al.  Protection against influenza virus challenge by topical application of influenza DNA vaccine. , 2001, Vaccine.

[50]  A R Rees,et al.  Humanization of murine monoclonal antibodies through variable domain resurfacing. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[51]  W. Fiers,et al.  A "universal" human influenza A vaccine. , 2004, Virus research.

[52]  L. Otvos,et al.  Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. , 2003, Vaccine.

[53]  W. Marasco,et al.  The growth and potential of human antiviral monoclonal antibody therapeutics , 2007, Nature Biotechnology.

[54]  N. Tsurushita,et al.  Design of humanized antibodies: from anti-Tac to Zenapax. , 2005, Methods.

[55]  W. C. Gamble,et al.  Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. , 1995, Vaccine.

[56]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[57]  T. Randall,et al.  A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus1 , 2008, The Journal of Immunology.

[58]  H. Klenk,et al.  New low-viscosity overlay medium for viral plaque assays , 2006, Virology Journal.

[59]  Enrique Vargas‐Madrazo,et al.  An improved model of association for VH–VL immunoglobulin domains: Asymmetries between VH and VL in the packing of some interface residues , 2003, Journal of molecular recognition : JMR.

[60]  S. Epstein.  Control of influenza virus infection by immunity to conserved viral features , 2003, Expert review of anti-infective therapy.

[61]  R. Stevens,et al.  Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin , 2007, Nature Biotechnology.

[62]  T. Uyeki,et al.  A national survey of severe influenza-associated complications among children and adults, 2003-2004. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  R. Lamb,et al.  Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice , 1990, Journal of virology.

[64]  A. Bradbury,et al.  Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models , 2007, BMC Biotechnology.

[65]  G L Ada,et al.  Options for the control of influenza III. Cairns, North Queensland, Australia (4-9 May 1996). , 1997, Vaccine.

[66]  F. M. Davenport.  CONTROL OF INFLUENZA , 1973, The Medical journal of Australia.